Jakub Czarny

Mr. Jakub Czarny

Poznan University of Medical Sciences, Poznań, Wielkopolskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
WSWojciech Kacper Szlasa
Wojciech Kacper Szlasa
JCJakub Czarny
Jakub Czarny
NSNatalia Sauer
Natalia Sauer
KRKatarzyna Anna Rakoczy
Katarzyna Anna Rakoczy
NSNatalia Szymańska
Natalia Szymańska
EBEwa Barg
Ewa Barg
CD38 is a myeloid antigen present both on the cell membrane and in the intracellular compartment of the cell. Its occurrence is often enhanced in cancer cells, thus making it a potential target in anticancer therapy. Daratumumab and isatuximab already received FDA approval, and novel agents such as MOR202, TAK079 and TNB-738 undergo clinical trials. Also, novel therapeutics such as SAR442085 aim to outrank the older antibodies against CD38. Multiple myeloma and immunoglobulin light-chain amyloidosis may be effectively treated with anti-CD38 immunotherapy. Its role in other hematological malignancies is also important concerning both diagnostic process and potential treatment in the future. Aside from the hematological malignancies, CD38 remains a potential target in gastrointestinal, neurological and pulmonary system disorders. Due to the strong interaction of CD38 with TCR and CD16 on T cells, it may also serve as the biomarker in transplant rejection in renal transplant patients. Besides, CD38 finds its role outside oncology in systemic lupus erythematosus and collagen-induced arthritis. CD38 plays an important role in viral infections, including AIDS and COVID-19. Most of the undergoing clinical trials focus on the use of anti-CD38 antibodies in the therapy of multiple myeloma, CD19- B-cell malignancies, and NK cell lymphomas. This review focuses on targeting CD38 in cancer and non-cancerous diseases using antibodies, cell-based therapies and CD38 inhibitors. We also provide a summary of current clinical trials targeting CD38.

12 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MAMarta Anna Andrzejewska
Marta Anna Andrzejewska
JCJakub Czarny
Jakub Czarny
KDKatarzyna Derwich
Katarzyna Derwich
Gastrointestinal stromal tumor is the most common mesenchymal neoplasm of the gastrointestinal tract, usually found in elderly adults. It is infrequent among pediatric patients and usually differs biologically from adult-type diseases presenting mutations of KIT and PDGFR genes. In this population, more frequent is the wild-type GIST possessing SDH, TRK, RAS, NF1 mutations, among others. Both tumor types require individualized treatment with kinase inhibitors that are still being tested in the pediatric population due to the different neoplasm biology. We review the latest updates to the management of pediatric gastrointestinal tumors with a particular focus on the advances in molecular biology of the disease that enables the definition of possible resistance. Emerging treatment with kinase inhibitors that could serve as targeted therapy is discussed, especially with multikinase inhibitors of higher generation, the effectiveness of which has already been confirmed in the adult population.

4 August 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MKMikołaj Kamiński
Mikołaj Kamiński
JCJakub Czarny
Jakub Czarny
PSPiotr Jerzy Skrzypczak
Piotr Jerzy Skrzypczak
KSKrzysztof Sienicki
Krzysztof Sienicki
MRMagdalena Roszak
Magdalena Roszak
Background: The internet is a primary source of health information for patients, supplementing physician care. Google Trends (GT), a popular tool, allows the exploration of public interest in health-related phenomena. Despite the growing volume of GT studies, none have focused explicitly on oncology, creating a need for a systematic review to bridge this gap. Objective: We aimed to systematically characterize studies related to oncology using GT to describe its utilities and biases. Methods: We included all studies that used GT to analyze Google searches related to malignancies. We excluded studies written in languages other than English. The search was performed using the PubMed engine on August 1, 2022. We used the following search input: “Google trends” AND (“oncology” OR “cancer” or “malignancy” OR “tumor” OR “lymphoma” OR “multiple myeloma” OR “leukemia”). We analyzed sources of bias that included using search terms instead of topics, lack of confrontation of GT statistics with real-world data, and absence of sensitivity analysis. We performed descriptive statistics. Results: A total of 85 articles were included. The first study using GT for oncology research was published in 2013, and since then, the number of publications has increased annually. The studies were categorized as follows: 22% (19/85) were related to prophylaxis, 20% (17/85) pertained to awareness events, 11% (9/85) were celebrity-related, 13% (11/85) were related to COVID-19, and 47% (40/85) fell into other categories. The most frequently analyzed cancers were breast (n=28), prostate (n=26), lung (n=18), and colorectal cancers (n=18). We discovered that of the 85 studies, 17 (20%) acknowledged using GT topics instead of search terms, 79 (93%) disclosed all search input details necessary for replicating their results, and 34 (40%) compared GT statistics with real-world data. The most prevalent methods for analyzing the GT data were correlation analysis (55/85, 65%) and peak analysis (43/85, 51%). The authors of only 11% (9/85) of the studies performed a sensitivity analysis. Conclusions: The number of studies related to oncology using GT data has increased annually. The studies included in this systematic review demonstrate a variety of concerning topics, search strategies, and statistical methodologies. The most frequently analyzed cancers were breast, prostate, lung, colorectal, skin, and cervical cancers, potentially reflecting their prevalence in the population or public interest. Although most researchers provided reproducible search inputs, only one-fifth used GT topics instead of search terms, and many studies lacked a sensitivity analysis. Scientists using GT for medical research should ensure the quality of studies by providing a transparent search strategy to reproduce results, preferring to use topics over search terms, and performing robust statistical calculations coupled with sensitivity analysis.

Verified
Journal Article
Open access
PDF file
JCJakub Czarny
Jakub Czarny
MAMarta Anna Andrzejewska
Marta Anna Andrzejewska
OZOlga Zajac-Spychala
Olga Zajac-Spychala
ELElżbieta Latos-Grażyńska
Elżbieta Latos-Grażyńska
APAgata Pastorczak
Agata Pastorczak
KDKatarzyna Derwich
Katarzyna Derwich
Ataxia-telangiectasia (AT) is a multisystemic neurodegenerative inborn error of immunity (IEI) characterized by DNA repair defect, chromosomal instability, and hypersensitivity to ionizing radiation. Impaired DNA double-strand break repair determines a high risk of developing hematological malignancies, especially lymphoproliferative diseases. Poor response to treatment, excessive chemotherapy toxicities, and the need for avoiding exposure to ionizing radiation make the successful clinical management of patients with AT challenging for oncologists. We describe the favorable outcome of the LBCL with IRF4 rearrangement at stage III in a 7-year-old female patient diagnosed with AT. The patient was treated according to the B-HR arm of the INTER-B-NHL-COP 2010 protocol, including the administration of rituximab, cyclophosphamide, methotrexate, prednisone, etc. She presented excessive treatment toxicities despite individually reduced doses of methotrexate and cyclophosphamide. However, in the MRI there was no significant reduction in pathologic lymph nodes after three immunochemotherapy courses. Therefore, a lymph node biopsy was taken. Its subsequent histopathological examination revealed tuberculosis-like changes, though tuberculosis suspicion was excluded. After two following immunochemotherapy courses, PET-CT confirmed complete remission. From March 2022 onwards, the patient has remained in remission under the care of the outpatient children’s oncology clinic.

Verified
Journal Article
Open access
PDF file
MKMaksymilian Kolodziej
Maksymilian Kolodziej
JCJakub Czarny
Jakub Czarny
HDHanna Dyła
Hanna Dyła
DRDominika Rękawek
Dominika Rękawek
MZMaria Złotek
Maria Złotek
Hanna Dams-KozłowskaHanna Dams-Kozłowska
Hanna Dams-Kozłowska
There is a growing pressure for further breast cancer treatment development to improve patient quality of life and clinical effectiveness while reducing drug resistance and side effects. Clinical research, however, remains both expensive and time-consuming, highlighting the importance of advancing preclinical studies. The ability of a model to accurately replicate the biological environment is essential for generating reliable data. Although research on two-dimensional in vitro cell culture systems has been conducted for over a century, their limited complexity hinders further development of cancer treatments. Consequently, the response to tested medications is artificial, since some drugs appear to be effective only in the two-dimensional model and not in clinical settings. A multicellular spheroid (MCS) is a three-dimensional assembly of cancer cells, used in oncology to study cancer biology and drug sensitivity. MCSs serve as valuable in vitro models in preclinical drug development. They can also be used in a clinical setting as a personalized tool for drug susceptibility screening. The objective of this review is to highlight new possibilities for improved anticancer drug screening and the development of personalized treatment regimens with multicellular spheroids.

6 October 2026 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
PKPaulina Kalman
Paulina Kalman
JCJakub Czarny
Jakub Czarny
NSNatalia Siwak
Natalia Siwak
KPKatarzyna Pietroniec
Katarzyna Pietroniec
BWBartosz Wojewoda
Bartosz Wojewoda
KPKatarzyna Pogoda
Katarzyna Pogoda
Introduction: Breast cancer is the most common malignancy among women in Poland, yet participation in the national mammography screening programme remains low (approximately 30%). Medical trainees play a crucial role in promoting prevention, but their preparation in this area is insufficiently explored. Material and methods: A cross-sectional online survey was conducted among students from 10 Polish medical universities and doctors-in-training (from November 2024 to February 2025). The questionnaire assessed knowledge of screening guidelines, exposure to curricular training, and self-reported competence in clinical breast examination (CBE). Descriptive statistics and tests were used to analyse associations between categorical variables. Results: A total of 1,245 participants were included. Nearly half (48.7%) had never been taught CBE, and only 4% had practised with patients. While most respondents recognised mammography as an effective screening tool (96.4%), only 24.1% correctly identified both the screening interval and eligible age group. Attendance at curricular classes was significantly associated with better knowledge, higher confidence in performing CBE independently (p < 0.001), and greater comfort discussing breast self-examination with patients (85% vs. 76%, p < 0.001). Conclusions: This nationwide study highlights major gaps in breast cancer prevention education among Polish medical trainees. Although general awareness of mammography is high, understanding of programme details and practical CBE skills remains limited. Structured, competency-based curricula incorporating hands-on and simulation-based training are needed to strengthen preventive oncology education and support efforts to increase screening participation in Poland.